Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA) (ELITRA)

A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR® pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dose of Inhaled Corticosteroids.

Primary objective

The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory volume in the first second (FEV1) area under the curve between time 0 and 12 hours (AUC0-12h) normalised by time on Day 42.

Key secondary objective

The key secondary objective was to evaluate the superiority of CHF 5259 pMDI (50 μg total daily dose) versus placebo in terms of peak FEV1 on Day 42.

Secondary objectives

The secondary objectives were:

• To evaluate the effect of CHF 5259 pMDI on other lung function parameters and on clinical outcome measures;
• To assess the safety and tolerability of study medications.

Study Overview

• Status: Completed
• Conditions: Asthma
• Intervention / Treatment: Drug: CHF 5259 12.5 µg + Qvar; Drug: CHF 5259 placebo + Qvar

Detailed Description

This was a phase IIb, multicentre, randomised, double-blind, placebo-controlled, 2-way crossover study consisting of two 6-week treatment periods (42 days each ±2 days), separated by a 1-week washout period (+2 days). The study employed a complete block design and a multiple-dosing regimen. It was designed as an add-on therapy to evaluate the efficacy and safety of CHF 5259 pMDI when used in combination with Qvar® pMDI in patients with uncontrolled asthma on low-to-medium doses of inhaled corticosteroids (ICS).

The crossover design was chosen because each patient serves as their own control, thereby reducing variability caused by inter-patient differences and minimizing the effects of potential confounding factors. This design improve statistical power, allowing for estimation of comparisons between treatments with a smaller sample size compared to a parallel arms study. The study aimed to randomise 98 patients to ensure at least 68 evaluable participants, accounting for an estimated 30% dropout or non-evaluable rate.

The study included the following phases:

• Pre-Screening Phase (Visit [V] 0): Conducted within 7 days prior to the Screening Visit, this visit aimed to explain the study to potential participants, obtain informed consent, and instruct patients on procedures for the Screening Visit.
• Screening Phase (Visit 1): This visit assessed eligibility for inclusion in the study and transitioned participants from their previous ICS therapy to a clinically equivalent dose of Qvar® pMDI (ranging from 50 μg to 400 μg daily). The Qvar® regimen was maintained as background therapy throughout the study. The Screening Visit was followed by a 2-week open-label run-in phase (±2 days) with Qvar® pMDI to ensure baseline standardization without compromising disease control.
• Investigational Phase:

Comprised two treatment periods:

1. Treatment Period 1 (P1): Spanning 42 days, starting at randomisation (Visit 2) and ending at Day 42 (Visit 3).
2. Treatment Period 2 (P2): Spanning another 42 days, starting at Visit 4 (Day 1 of Period 2) and concluding at Visit 5 (Day 42 of Period 2).

During these periods, patients received two puffs of their assigned treatment (CHF 5259 or placebo) twice daily (morning and evening), in addition to their stable Qvar® therapy.

A 1-week washout period (+2 days) was implemented between the two treatment periods to minimize the potential for carryover effects from the first treatment period.

• Follow-Up Phase: One week (+2 days) after the final treatment visit (Visit 5) or early termination, a follow-up phone call was conducted to assess unresolved adverse events (AEs) and document any new AEs or concomitant medications.

Overall, the study lasted 17 weeks per participant, including a 1-week pre-screening period; the 2-week run-in period; two 6-week treatment periods, and the follow-up phase. The two 6-week treatment periods allowed sufficient time for the evaluation of efficacy endpoints, while the 1-week washout period was deemed adequate to eliminate residual treatment effects.

• Study Type: Interventional
• Enrollment (Actual): 98
• Phase: Phase 2

Contacts and Locations

Study Locations

• Bulgaria
  • Rousse, Bulgaria, 7002
    • Chiesi Clinical Trial Site 0107
  • Sevlievo, Bulgaria, 5400
    • Chiesi Clinical Trial Site 0106
  • Sofia, Bulgaria, 1000
    • Chiesi Clinical Trial Site 0101
  • Sofia, Bulgaria, 1336
    • Chiesi Clinical Trial Site 0109
  • Sofia, Bulgaria, 1407
    • Chiesi Clinical Trial Site 0108
  • Sofia, Bulgaria, 1431
    • Chiesi Clinical Trial Site 0102
  • Sofia, Bulgaria, 1431
    • Chiesi Clinical Trial Site 0103
• Germany
  • Berlin, Germany, D-12165
    • Chiesi Clinical Trial Site 0201
  • Leipzig, Germany, 04207
    • Chiesi Clinical Trial Site 0203
  • Leipzig, Germany, 04357
    • Chiesi Clinical Trial Site 0202
  • Magdeburg, Germany, 39112
    • Chiesi Clinical Trial Site 0206
  • Radebeul, Germany, 01445
    • Chiesi Clinical Trial Site 0207
  • Witten, Germany, 58452
    • Chiesi Clinical Trial Site 0208
• Italy
  • Brescia, Italy, 25123
    • Chiesi Clinical Trial Site 0306
  • Pisa, Italy, 56124
    • Chiesi Clinical Trial Site 0301
  • Pisa, Italy, 56124
    • Chiesi Clinical Trial Site 0304
  • Pordenone, Italy, 33170
    • Chiesi Clinical Trial Site 0303
• Netherlands
  • Assen, Netherlands, 9401 RK
    • Chiesi Clinical Trial Site 0404
  • Helmond, Netherlands, 5707 HA
    • Chiesi Clinical Trial Site 0405
• Poland
  • Bialystok, Poland, 15-010
    • Chiesi Clinical Trial Site 0501
  • Bialystok, Poland, 15-351
    • Chiesi Clinical Trial Site 0502
  • Elblag, Poland, 82-300
    • Chiesi Clinical Trial Site 0503
  • Krakow, Poland, 30-349
    • Chiesi Clinical Trial Site 0507
  • Krakow, Poland, 31-011
    • Chiesi Clinical Trial Site 0504
  • Lodz, Poland, 90-141
    • Chiesi Clinical Trial Site 0512
  • Lodz, Poland, 90-252
    • Chiesi Clinical Trial Site 0510
  • Wroclaw, Poland, 53-310
    • Chiesi Clinical Trial Site 0505
  • Zgierz, Poland, 95-100
    • Chiesi Clinical Trial Site 0506

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient's written informed consent obtained prior to any study related procedures;
2. Male or female patients aged ≥18 and ≤75 years;
3. History of asthma ≥5 year and diagnosed before the age of 40 years;
4. Patients with uncontrolled asthma on low medium doses of ICS (200 - 1000 μg daily dose BDP non-extrafine or estimated clinical comparable dose) at a stable dose for at least 4 weeks prior to Screening visit;
5. Patients with a pre bronchodilator FEV1 ≥40% and <90% of their predicted normal value, after appropriate washout from bronchodilators, at Screening visit and the end of the run in period;
6. Patients with a positive response to the reversibility test at Screening visit within 30 minutes after administration of 400 μg of salbutamol pMDI, defined as ΔFEV1 ≥12% and ≥200 mL over baseline; Note: In case this reversibility threshold was not met, the test could have been performed once before randomisation.
7. Patients with uncontrolled asthma evidenced by a score at the Asthma Control Questionnaire® (ACQ) ≥1.5 (criterion had to be met at Screening visit and the end of the run in period);
8. Patients with a co-operative attitude and ability to be trained to correctly use the pMDI and the electronic peak flow meter (e-peak flow meter). At the Screening visit (V1), all the above mentioned inclusion criteria were checked. At the Randomisation visit (V2), the following inclusion criteria were re checked: 5, 7 and 8.

Exclusion Criteria:

1. Inability to carry out pulmonary lung function testing, to comply with study procedures or with study medication intake;
2. History of near fatal asthma or of a past hospitalisation for asthma in intensive care unit or of frequent exacerbations in the last year which, in the judgement of the Investigator, may have placed the patient at risk;
3. Hospitalisation, emergency room admission or use of systemic corticosteroids for asthma exacerbation in the 4 weeks prior to Screening visit or during the run-in period;
4. Lower respiratory tract infection in the 4 weeks before Screening visit or during the run-in period;
5. Patients who were in current therapy for gastroesophageal reflux disease (GERD) or patients with a medical history of GERD that led to asthma symptoms;
6. Patients with a seasonal worsening of asthma and who were not able to complete the study outside the relevant allergen season;
7. History of cystic fibrosis, bronchiectasis or alpha 1 antitrypsin deficiency, bronco carcinoma, lung carcinoma or any other significant lung disease which may have interfered with data evaluation;
8. Patients with a medical history or current diagnosis of COPD as defined by the Global Initiative for chronic obstructive lung disease (GOLD) guidelines (2014);
9. Current smokers or ex-smokers with total cumulative exposure equal or more than 10 pack years or having stopped smoking one year or less prior to Screening visit;
10. Any change in dose, schedule or formulation of ICS in the 4 weeks prior to Screening visit;
11. Patient had used any of the following treatments 4 weeks before Screening visit: inhaled LABAs, inhaled LAMAs, inhaled ICS/LABA fixed combinations, theophylline,leukotriene modifiers, cromolyn sodium, nedocromil sodium, systemic anticholinergics, systemic corticosteroids (12 weeks for slow release corticosteroids);

12. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) unless are using at least one or more of the following reliable methods of contraception:

    1. Placement of an intrauterine device or intrauterine system;
    2. Hormonal contraception (implantable, injectable, patch, oral);
    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical vaults/caps) with spermicidal foam/gel/film/cream/suppository;
    4. Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate); Reliable contraception was maintained throughout the study and for 1 week after the last study dose. Pregnancy tests were performed at study entry (a serum test at Screening visit and a urinary test at Screening and Randomisation visits) in all women of childbearing potential.

    Any postmenopausal women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilised (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) were enrolled in the study.

13. Patients who received any investigational new drug or participated in clinical study either within the last 8 weeks (or 5 half-lives for biologic products with slow elimination) before Screening visit;
14. Patients who had clinically significant (CS) cardiovascular condition according to Investigator's judgement such as but not limited to: congestive heart failure (New York Heart Association [NYHA] class >3), acute ischemic heart disease in the last year prior to study Screening, history of sustained cardiac arrhythmias or sustained and non-sustained cardiac arrhythmias diagnosed in the last 6 months (sustained means lasting more than 30 seconds or ending only with external action, or leads to hemodynamic collapse; non-sustained means >5 beats <30 seconds), impulse conduction blocks. Similarly, patients affected by permanent or paroxysmal atrial fibrillation were not considered for enrolment;
15. An abnormal and CS 12-lead electrocardiogram (ECG) that resulted in active medical problem which may have impacted the safety of the patient according to Investigator's judgement;
16. Patients whose electrocardiogram (12-lead ECG) showed Fridericia corrected QT (QTcF) >450 ms for males or QTcF >470 ms for females at Screening or at Randomisation visits;
17. Medical diagnosis of narrow angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator, prevented use of anticholinergic agents;
18. Unstable concurrent disease: e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; with moderate to severe renal impairment (known creatinine clearance of ≤50 mL/min); uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled neurological disease; uncontrolled haematological disease; uncontrolled autoimmune disorders, or other laboratory abnormality that may have increased the risk associated with study participation or study medications administration and, in the judgment of theInvestigator, made the patient inappropriate for entry into this study, or placed the patients at undue risk or potentially compromised the results or interpretation of the study;
19. Patients having received a live attenuated virus vaccination within two weeks prior to Screening or during the run-in (inactivated influenza vaccination was acceptable provided it was not administered less than 48 hours prior to Screening);
20. Patients mentally or legally incapacitated;
21. Patients with a history of alcohol or drug abuse;
22. Patients with known intolerance/hypersensitivity or contra indication to treatment with β2 agonists, inhaled corticosteroids, anti cholinergics or propellant gases/excipients;
23. Patients with major surgery in the 3 months prior to Screening visit or planned surgery during the trial;
24. Patients treated with anti IgE antibodies;
25. Patients treated with non-potassium sparing diuretics (unless administered as a FDC with a potassium conserving drug), non-selective beta blocking drugs (except if taken at stable regimen for at least 2 months before Screening), quinidine, quinidine like anti arrhythmics, or any medication with a QTc prolongation potential or a history of QTc prolongation;
26. Patients treated with monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants;
27. Patients who are receiving any therapy that could have interfered with the study medications according to Investigator's opinion. At the Screening visit (V1), all the above mentioned exclusion criteria were checked. At the Randomisation visit (V2), the following exclusion criteria were re-checked: 1, 2, 3, 4, 5, 12, 15, 16, 18, 19, 23 and 27.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: sequence CHF 5259 pMDI - placebo pMDI + Qvar; In this sequence, patients received: CHF 5259 pMDI (Active Treatment): CHF 5259 pMDI 12.5 µg as two puffs twice daily (b.i.d.), for a total daily dose of 50 µg, administered via metered dose inhalation of pressurised solution using a standard actuator. Treatment duration: 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg. Wash-Out Period (1 Week): Qvar® pMDI 50 µg or 100 µg b.i.d., administered via metered dose inhalation of pressurised solution, with a daily dose ranging from 100 µg to 400 µg. Placebo of CHF 5259 pMDI (Control Treatment): A matched placebo for CHF 5259 pMDI, administered via metered dose inhalation of pressurised solution using a standard actuator. Treatment duration: 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg.	Drug: CHF 5259 12.5 µg + Qvar; comparison of CHF 5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days; Other Names: glycopyrrolate bromide; Drug: CHF 5259 placebo + Qvar; comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days; Other Names: Placebo
Other: sequence placebo pMDI - CHF 5259 pMDI + Qvar; In this sequence, patients received: Placebo of CHF 5259 pMDI (Control Treatment): A matched placebo for CHF 5259 pMDI, administered via metered dose inhalation using a standard actuator for 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg. Wash-Out Period (1 Week): Qvar® pMDI 50 µg or 100 µg b.i.d., administered via metered dose inhalation using a standard actuator, with a daily dose ranging from 100 µg to 400 µg. CHF 5259 pMDI (Active Treatment): CHF 5259 pMDI 12.5 µg as two puffs twice daily (b.i.d.), for a total daily dose of 50 µg, administered via metered dose inhalation using a standard actuator for 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg.	Drug: CHF 5259 12.5 µg + Qvar; comparison of CHF 5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days; Other Names: glycopyrrolate bromide; Drug: CHF 5259 placebo + Qvar; comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
FEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population)	FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.	Day 42
FEV1 AUC0-12h Normalized by Time on Day 42 (PP Population)	FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.	Day 42

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Peak FEV1 on Day 42 (ITT Population)	The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.	Baseline and Day 42
Change From Baseline in Peak FEV1 on Day 42 (PP Population)	The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.	Baseline and Day 42
FEV1 AUC0-12h Normalized by Time on Day 1	FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose on Day 1 post-dose.	Day 1
FEV1 AUC0-3h Normalised by Time on Day 1	AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was assessed at 15 min, 30 min, 45 min, 1h, 2h, 3h on day 1.	Day 1
FEV1 AUC0-3h Normalised by Time on Day 42	AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h. on day 1 and on day 42	Day 42
Change From Baseline in Peak FEV1 on Day 1	The peak FEV1 is determined as the maximum FEV1 value obtained between 15 minutes and 12 hours post-dose. The baseline value is the mean of the pre-dose measurement of FEV1 at Day 1 of each treatment period.	Baseline and Day 1
Change From Baseline in Pre-dose Morning Through FEV1 on Day 42	The pre-dose morning FEV1 is defined as the mean of the two measurements at 45 and 15 minutes predose.	Baseline and Day 42
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 1	Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.	Baseline and Day 1
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 42	Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.	Baseline and Day 42
Average Daily PEF (Morning and Evening) During Treatment Periods	PEF = Peak Expiratory Flow. PEF was measured at home by patients using a portable e-peak flow meter (AM3 device). Patients were educated on the purpose and technique of PEF home monitoring and specific instructions for use were made available to them. During the run-in/wash-out and the two treatment periods (from V1 to V5), PEF was monitored twice daily, in the morning and in the evening, before the intake of the background medication or study medication. PEF was also assessed during the visits only for information purpose of the Investigator. During each measurement session, the patient performed 3 blows and data were recorded in the device. The average daily morning PEF is the mean value of all morning PEF measurements. The average daily evening PEF is the mean value of all evening PEF measurements. Please note: the average daily morning PEF and the average daily evening PEF during the treatment periods are reported.	Twice Daily during treatment periods (from V1 to V5)
Average Daily Asthma Symptoms (Daytime) During Treatment Periods	Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Daytime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom; = Mild: aware of symptoms which can be easily tolerated; = Moderate: discomfort causing interference with daily activity; = Severe: inability to work/make usual activity The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score daytime = Σ〖Cough daytime score + Wheeze daytime score + Chest Tightness daytime scoreBreathlessness daytime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.	During treatment periods (from V2 to V5), up to 6 weeks
Average Daily Asthma Symptoms (Nighttime) During Treatment Periods	Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Nighttime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom; = Mild: symptoms not causing awakening; = Moderate: discomfort causing awakenings; = Severe: causing awakenings for most of the night / don't allow to sleep at all The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score nighttime = Σ〖Cough nighttime score + Wheeze nighttime score + Chest Tightness nighttime score + Breathlessness nighttime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.	Daily during treatment periods (from V2 to V5)
Percentage of Asthma Control Days During the Treatment Periods	An asthma control day is derived from patient diary data, and is defined as days on which the patient meets both of the following criteria: a total asthma symptom score (daytime + nighttime) of 0, indicating no symptoms such as cough, wheeze, chest tightness, or breathlessness, and no use of rescue medication during the day.The percentage of control days is calculated as the number of asthma control days / number of days with available data.	During the treatment periods (from V2 to V5)
Average Use of Rescue Medication (Number of Puffs/Day)	The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the first parameter is reported.	During the treatment periods (from V2 to V5)
Average Use of Rescue Medication (Number of Times/Day)	The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the second parameter is reported.	During the treatment periods (from V2 to V5)
Change From Baseline in Asthma Control Questionnaire (ACQ) Total Score on Day 42	The ACQ is a validated questionnaire rating patient asthma control. It has a multidimensional construct assessing symptoms (5 questions-self-administered) and rescue bronchodilator use (1 question-self-administered), and FEV1% predicted (1 question answered by clinicians). For each of the 7 questions, possible answer could score from 0 (no impairment for symptoms and rescue use) to 6 (maximum impairment for symptoms and rescue use). The questions are equally weighted and the ACQ total score is the mean of the 7 questions and therefore between 0 (asthma totally controlled) and 6 (asthma severely uncontrolled).	Baseline and Day 42
Change From Baseline in FVC on Day 1	FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.	Baseline and Day 1
Change From Baseline in FVC on Day 42	FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.	Baseline and Day 42

Other Outcome Measures

Outcome Measure	Time Frame
Adverse Events and Adverse Drug reactions	Up to 17 Weeks

Collaborators and Investigators

• Sponsor: Chiesi Farmaceutici S.p.A.
• Investigators: Principal Investigator: prof. Pierluigi Paggiaro, MD, Dip. Cardio-Toracico e Vascolare Malattie dell'Apparato respiratorio, Ospedale Cisanello, Pisa

Publications and helpful links

Helpful Links

• Study Record on EU Clinical Trials Register including results

Study record dates

Study Major Dates

• Study Start (Actual): November 21, 2014
• Primary Completion (Actual): August 13, 2015
• Study Completion (Actual): August 13, 2015

Study Registration Dates

• First Submitted: November 14, 2014
• First Submitted That Met QC Criteria: November 18, 2014
• First Posted (Estimated): November 20, 2014

Study Record Updates

• Last Update Posted (Actual): April 22, 2026
• Last Update Submitted That Met QC Criteria: April 20, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Corticosteroids; Asthma, Anticholinergics; CHF 5259 pMDI; Qvar® pMDI add-on therapy
• Additional Relevant MeSH Terms: Immune System Diseases; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Asthma; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Polycyclic Compounds; Amines; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Pregnadienetriols; Quaternary Ammonium Compounds; Onium Compounds; Pyrrolidines; Steroids, Chlorinated; Beclomethasone; Glycopyrrolate
• Other Study ID Numbers: CCD-05993AB1-02; 2014-001442-16 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.

Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

• IPD Sharing Access Criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No